Next Article in Journal
L-Ferritin: One Gene, Five Diseases; from Hereditary Hyperferritinemia to Hypoferritinemia—Report of New Cases
Next Article in Special Issue
Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells
Previous Article in Journal
Micellisation Mechanism and Behaviour of Soluplus®–Furosemide Micelles: Preformulation Studies of an Oral Nanocarrier-Based System
Previous Article in Special Issue
Cyclooxygenase-1 (COX-1) and COX-1 Inhibitors in Cancer: A Review of Oncology and Medicinal Chemistry Literature
Open AccessReview

Can the Efficacy of [18F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles?

1
Trinity Translational Medicine Institute, Department of Surgery, Trinity College Dublin, D08W9RT Dublin, Ireland
2
Department of Radiology, St. James’s Hospital, D08 X4RX Dublin, Ireland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(1), 16; https://doi.org/10.3390/ph12010016
Received: 18 December 2018 / Revised: 3 January 2019 / Accepted: 14 January 2019 / Published: 23 January 2019
(This article belongs to the Special Issue Anticancer Drugs)
Positron Emission Tomography (PET) is a functional imaging modality widely used in clinical oncology. Over the years the sensitivity and specificity of PET has improved with the advent of specific radiotracers, increased technical accuracy of PET scanners and incremental experience of Radiologists. However, significant limitations exist—most notably false positives and false negatives. Additionally, the accuracy of PET varies between cancer types and in some cancers, is no longer considered a standard imaging modality. This review considers the relative influence of macroscopic tumour features such as size and morphology on 2-Deoxy-2-[18F]fluoroglucose ([18F]FDG) uptake by tumours which, though well described in the literature, lacks a comprehensive assessment of biomolecular features which may influence [18F]FDG uptake. The review aims to discuss the potential influence of individual molecular markers of glucose transport, glycolysis, hypoxia and angiogenesis in addition to the relationships between these key cellular processes and their influence on [18F]FDG uptake. Finally, the potential role for biomolecular profiling of individual tumours to predict positivity on PET imaging is discussed to enhance accuracy and clinical utility. View Full-Text
Keywords: [18F]FDG PET/CT; biomarker profiling; cancer [18F]FDG PET/CT; biomarker profiling; cancer
Show Figures

Graphical abstract

MDPI and ACS Style

O’Neill, H.; Malik, V.; Johnston, C.; Reynolds, J.V; O’Sullivan, J. Can the Efficacy of [18F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles? Pharmaceuticals 2019, 12, 16. https://doi.org/10.3390/ph12010016

AMA Style

O’Neill H, Malik V, Johnston C, Reynolds JV, O’Sullivan J. Can the Efficacy of [18F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles? Pharmaceuticals. 2019; 12(1):16. https://doi.org/10.3390/ph12010016

Chicago/Turabian Style

O’Neill, Hazel; Malik, Vinod; Johnston, Ciaran; Reynolds, John V; O’Sullivan, Jacintha. 2019. "Can the Efficacy of [18F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles?" Pharmaceuticals 12, no. 1: 16. https://doi.org/10.3390/ph12010016

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop